TA-1801 structure
|
Common Name | TA-1801 | ||
---|---|---|---|---|
CAS Number | 88352-44-7 | Molecular Weight | 331.75000 | |
Density | 1.275g/cm3 | Boiling Point | 471ºC at 760 mmHg | |
Molecular Formula | C17H14ClNO4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 238.6ºC |
Use of TA-1801TA-1801 is a hypolipidemic agent. |
Name | ethyl 2-[2-(4-chlorophenyl)-5-(furan-2-yl)-1,3-oxazol-4-yl]acetate |
---|---|
Synonym | More Synonyms |
Description | TA-1801 is a hypolipidemic agent. |
---|---|
Related Catalog | |
In Vitro | TA-1801 inhibits platelet aggregation in vitro[1]. |
In Vivo | TA-1801 reduces serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it is about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats[1]. |
References |
Density | 1.275g/cm3 |
---|---|
Boiling Point | 471ºC at 760 mmHg |
Molecular Formula | C17H14ClNO4 |
Molecular Weight | 331.75000 |
Flash Point | 238.6ºC |
Exact Mass | 331.06100 |
PSA | 65.47000 |
LogP | 4.36060 |
Index of Refraction | 1.556 |
Storage condition | 2-8℃ |
~83% TA-1801 CAS#:88352-44-7 |
Literature: Moriya; Seki; Takabe; Matsumoto; Takashima; Mori; Odawara; Takeyama Journal of Medicinal Chemistry, 1988 , vol. 31, # 6 p. 1197 - 1204 |
~% TA-1801 CAS#:88352-44-7 |
Literature: Moriya; Seki; Takabe; Matsumoto; Takashima; Mori; Odawara; Takeyama Journal of Medicinal Chemistry, 1988 , vol. 31, # 6 p. 1197 - 1204 |
~% TA-1801 CAS#:88352-44-7 |
Literature: Moriya; Seki; Takabe; Matsumoto; Takashima; Mori; Odawara; Takeyama Journal of Medicinal Chemistry, 1988 , vol. 31, # 6 p. 1197 - 1204 |
~% TA-1801 CAS#:88352-44-7 |
Literature: Moriya; Seki; Takabe; Matsumoto; Takashima; Mori; Odawara; Takeyama Journal of Medicinal Chemistry, 1988 , vol. 31, # 6 p. 1197 - 1204 |
Precursor 3 | |
---|---|
DownStream 0 |
ta 1801 |
TA-1801 |